# REGN earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/REGN) · [Earnings tab](https://www.lopjlb.com/stock/REGN?tab=earnings) Updated: 2026-10-30T06:17:09 Quarters analyzed: 8 ## Cross-quarter narrative Across the series of Regeneron CallCards the company moved from a phase of strong revenue growth and multiple on‑track readouts (2024 Q3‑Q4) to a period marked by mounting execution pressures. Early calls highlighted Dupixent’s expanding indications and EYLEA HD’s promising data, while capital decisions were deferred pending the Sanofi balance. By Q4 2024 the firm initiated dividends and a $3 B buyback, yet pricing headwinds on EYLEA and safety questions on Activin A surfaced. The first‑half of 2025 introduced regulatory setbacks—most notably a complete‑response letter for the EYLEA HD pre‑filled syringe and manufacturing hiccups at third‑party sites—while biosimilar substitution eroded EYLEA volumes. Mid‑2025 saw continued margin compression from manufacturing investments and the emergence of trade‑tariff uncertainty. In 2026 the narrative shifted to resilient Dupixent demand and new share‑repurchase programs, but persistent FDA delays for the EYLEA HD syringe and broader operational risks remained. Throughout, the pipeline retained momentum with several late‑stage candidates advancing, yet timelines for key readouts (e.g., fianlimab‑Libtayo melanoma, Factor XI) slipped, underscoring a transition from growth optimism to a focus on navigating regulatory, manufacturing, and competitive challenges. ## Latest CallCard · Q2 Regeneron posted double‑digit revenue and earnings growth in Q2 2026, highlighted strong sales of Dupixent, EYLEA HD and Libtayo, and outlined multiple near‑term regulatory milestones while maintaining its 2026 guidance. **Guidance:** maintained — Management made modest refinements to 2026 guidance but did not materially change its outlook. **Tone:** mgmt 0.8 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks emphasized a strong quarter with double‑digit top‑ and bottom‑line growth and confidence in the pipeline. ### Demand visibility Robust demand across key products Dupixent sales up 38% YoY, EYLEA HD sales up 52% YoY and physician demand up 24% sequentially, Libtayo gaining market share in NSCLC. ### Margins / costs Margins stable, GAAP impacted by manufacturing hiccup Non‑GAAP gross margin 87%; GAAP 78% due to unabsorbed costs from a temporary bulk‑manufacturing interruption at the Limerick, Ireland facility, now resolved. ### Capital allocation Prioritizing internal R&D, disciplined M&A, active share repurchases R&D expense $1.5 B, $1.2 B of share repurchases in Q2, cash $15.1 B; no aversion to acquisitions but focus on value‑creating deals. ### Milestones - **Dupixent sales momentum** [on_track]: Global net sales $6 B, up 38% YoY, driving double‑digit growth. - **EYLEA HD prefilled syringe** [at_risk]: Target approval before year‑end; earlier Q2 timeline missed, renewed discussions with multiple CMOs. - **Cemdisiran FDA decision** [on_track]: FDA target action date November 2026 for gMG indication. - **Cemdisiran + Pozelimab PNH data** [on_track]: Registrational data expected Q4 2026, evaluating non‑inferiority to eculizumab. - **Long‑acting IL‑13 antibody first‑in‑human** [on_track]: Healthy‑subject enrollment complete; patient dosing later this quarter; aim registration‑enabling studies by early 2028. - **Factor XI Phase III VTE results** [on_track]: Pivotal results expected H1 2027 for venous thromboembolism prevention. - **Olatorepatide obesity program** [on_track]: Phase III data to be presented Oct at EASD; additional Phase III studies to start later this year. - **garetosmab FOP indication** [on_track]: FDA decision anticipated August 2026. ### Fears / risks - **Regulatory risk**: Approval timelines for cemdisiran, EYLEA HD syringe, olatorepatide and garetosmab are uncertain. - **Manufacturing risk**: Recent interruption at Limerick bulk‑manufacturing caused GAAP margin pressure. - **Commercial risk**: Dependence on Sanofi collaboration revenue and competitive dynamics for Dupixent follow‑on assets. - **Pipeline risk**: Late‑stage programs (Factor XI, obesity, oncology bispecifics) face clinical trial execution uncertainty. - **M&A valuation risk**: Management cautions against overpaying in acquisitions despite openness to deals. - **Competitive risk**: New therapies in myasthenia gravis, complement inhibition and obesity could limit market share. - **Supply chain risk**: Multiple CMOs engaged for EYLEA HD syringe may introduce coordination challenges. - **Financial risk**: Large cash balance and share repurchases could be constrained if guidance revisions occur. ### Key quotes > “Regeneron delivered another strong quarter with total revenues up 17% and non-GAAP earnings per share up 11% compared to the second quarter of 2025, making our second consecutive quarter of double-digit growth on both the top and bottom” > “Non-GAAP gross margin on net product sales was 87% in the second quarter. Our GAAP gross margin was 78%, which similar to the first quarter was negatively impacted by unabsorbed manufacturing costs related to the temporary interruption in” > “I don't think I expressed an aversion to M&A. I think I expressed an aversion to overpaying in M&A settings.” — Leonard Schleifer > “We could see this ending by the end of the year or sooner.” ## Quarter one-liners - **2026 Q2:** Regeneron posted double‑digit revenue and earnings growth in Q2 2026, highlighted strong sales of Dupixent, EYLEA HD and Libtayo, and outlined multiple near‑term regulatory milestones while maintaining its 2026 guidance. - **2026 Q1:** Regeneron Q1 2026 delivered double‑digit revenue growth driven by DUPIXENT and EYLEA HD, announced new share‑repurchase program, but faces FDA delays on an EYLEA HD prefilled syringe and a temporary manufacturing interruption affecting GAAP margin. - **2025 Q4:** Regeneron reported 3% revenue growth in Q4 2025, highlighted strong DUPIXENT, LIBTAYO and EYLEA HD sales, outlined multiple upcoming FDA approvals and an ambitious 2026 pipeline and capital deployment plan. - **2025 Q3:** — - **2025 Q2:** Regeneron posted strong Q2 sales growth driven by Dupixent, Libtayo and EYLEA HD, but faces FDA filing delays, pricing pressure and tariff uncertainty. - **2025 Q1:** Regeneron Q1 mixed: EYLEA sales down 39% on Avastin substitution, EYLEA HD up 54%, Dupixent +20% globally, pipeline advancing with multiple approvals and readouts, but EYLEA HD pre-filled syringe CRL creates near-term uncertainty. - **2024 Q4:** Regeneron reports 10% Q4 revenue growth, strong performance of Dupixent, Libtayo and EYLEA HD, outlines multiple upcoming approvals and data readouts, initiates a dividend and $3B buyback, while facing pricing pressure on EYLEA and safety questions on Activin A. - **2024 Q3:** Regeneron reported 11% revenue growth, highlighted Dupixent COPD approvals and strong EYLEA HD data, while outlining multiple upcoming readouts and deferring dividend/share‑repurchase plans until after its Sanofi balance payment. ## Theme arcs - **Dupixent growth and indication expansion** (improving): Consistently strong sales and new indication launches across calls - **EYLEA HD commercial performance** (deteriorating): Revenue pressure from biosimilar substitution and pricing headwinds - **Regulatory execution risk** (stable): Repeated FDA delays for multiple assets, especially EYLEA HD syringe - **Manufacturing and third‑party supplier risk** (deteriorating): Catalent inspections and component CRLs caused repeated delays - **Capital allocation strategy** (stable): Ongoing dividends, share‑repurchases and heavy R&D spend despite market pressures - **Pricing pressure on EYLEA** (deteriorating): Analyst notes and payer dynamics reduced contract terms - **Trade‑tariff uncertainty** (new): Potential 15% tariff discussed in 2025 Q2 onward - **Dupixent patent and royalty concerns** (new): Sanofi comments on IP horizon raised long‑term royalty questions ## Guidance path 2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:lowered → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:maintained → 2026 Q2:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/REGN`